Evidence map›Paper›PMID 29514211›Full record

ArticleThe Journal of antimicrobial chemotherapy2018

CTX-M ESBL-producing Enterobacteriaceae: estimated prevalence in adults in England in 2014.

Cliodna A M McNulty, Donna M Lecky, Li Xu-McCrae, Deborah Nakiboneka-Ssenabulya, Keun-Taik Chung, Tom Nichols, Helen Lucy Thomas, Mike Thomas, Adela Alvarez-Buylla, Kim Turner and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Advancements in AI-driven drug sensitivity testing research.Frontiers in cellular and infection microbiology · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Horsing around:Antimicrobial agents and chemotherapy · 2023
    Article
  12. Review
  13. Article
  14. Article
  15. Reduced Antibacterial Drug Resistance andApplied and environmental microbiology · 2021
    Article
  16. Article
  17. Article
  18. Article
  19. Emergence of diversity in carbapenemase-producingEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2019
    Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Cliodna A M McNultyPublic Health England, Primary Care Unit, Microbiology Department, Gloucester Royal Hospital, Great Western Road, Gloucester GL1 3NN, UK.
Donna M LeckyPublic Health England, Primary Care Unit, Microbiology Department, Gloucester Royal Hospital, Great Western Road, Gloucester GL1 3NN, UK.
Li Xu-McCraePublic Health England, Heart of England NHS Foundation Trust, Public Health Laboratory, Bordesley Green E, Birmingham B9 5SS, UK.
Deborah Nakiboneka-SsenabulyaPublic Health England, Primary Care Unit, Microbiology Department, Gloucester Royal Hospital, Great Western Road, Gloucester GL1 3NN, UK.
Keun-Taik ChungInstitute of Microbiology and Infection, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Tom NicholsPublic Health England, 61 Colindale Avenue, London NW9 5EQ, UK.
Helen Lucy ThomasPublic Health England, 61 Colindale Avenue, London NW9 5EQ, UK.
Mike ThomasUniversity of Southampton, Aldermoor Health Centre, Aldermoor Close, Southampton SO16 5ST, UK.
Adela Alvarez-BuyllaPublic Health England, Heart of England NHS Foundation Trust, Public Health Laboratory, Bordesley Green E, Birmingham B9 5SS, UK.
Kim TurnerPublic Health England, Primary Care Unit, Microbiology Department, Gloucester Royal Hospital, Great Western Road, Gloucester GL1 3NN, UK.
Sahida ShabirPublic Health England, Heart of England NHS Foundation Trust, Public Health Laboratory, Bordesley Green E, Birmingham B9 5SS, UK.
Susan ManzoorPublic Health England, Heart of England NHS Foundation Trust, Public Health Laboratory, Bordesley Green E, Birmingham B9 5SS, UK.
Stephen SmithUniversity Hospitals of Coventry & Warwickshire NHS Trust, Midlands & NW Bowel Cancer Screening Hub, Hospital of St Cross, Barby Road, Rugby CV22 5PX, UK.
Linda CrockerPublic Health England, Primary Care Unit, Microbiology Department, Gloucester Royal Hospital, Great Western Road, Gloucester GL1 3NN, UK.
Peter M HawkeyInstitute of Microbiology and Infection, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Gloucestershire Royal Hospital · GBHeart of England NHS Foundation Trust · GBPublic Health England · GBUniversity of Birmingham · GBHospital of St. Cross · GBUniversity of Southampton · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: ESBL-producing Enterobacteriaceae (ESBLPE) are increasing in prevalence worldwide and are more difficult to treat than non-ESBLPE. Their prevalence in the UK general population is unknown, as the only previous UK ESBLPE faecal colonization study involved patients with diarrhoea. Objectives: To estimate the prevalence of CTX-M ESBLPE faecal colonization in the general adult population of England in 2014, and investigate risk factors. Methods: A stratified random sample of 58 337 registered patients from 16 general practices within four areas of England were invited to participate by returning faeces specimens and self-completed questionnaires. Specimens were tested for ESBLPE and carbapenemase-producing Enterobacteriaceae (CPE). Results: 2430 individuals participated (4% of those invited). The estimated prevalence of colonization with CTX-M ESBLPE in England was 7.3% (95% CI 5.6%-9.4%) (Shropshire 774 participants, 4.9% colonization; Southampton City 740 participants, 9.2%; Newham 612 participants, 12.7%; Heart of Birmingham 234 individuals, 16.0%) and was particularly high in: those born in Afghanistan (10 participants, 60.0% colonization, 95% CI 29.7%-84.2%); those born on the Indian subcontinent (India, Pakistan, Bangladesh or Sri Lanka) (259 participants, 25.0% colonization, 95% CI 18.5%-32.9%); travellers to South Asia (India, Pakistan, Bangladesh, Sri Lanka or Nepal) in the last year (140 participants, 38.5% colonization, 95% CI 27.8%-50.5%); and healthcare domestics (8 participants, unweighted 37.5% colonization, 95% CI 8.5%-75.5%). Risk factors identified included: being born in the Indian subcontinent (aOR 5.4, 95% CI 3.0-9.7); travel to South Asia (aOR 2.9, 95% CI 1.8-4.8) or to Africa, China, South or Central America, South East or Pacific Asia or Afghanistan (aOR 2.6, 95% CI 1.7-4.1) in the last year; and working as a healthcare domestic (aOR 6.2, 95% CI 1.3-31). None of the 48 participants who took co-amoxiclav in the last year was colonized with CTX-M ESBLPE. blaCTX-M-15 accounted for 66% of CTX-M ESBLPE positives. 0.1% (two participants) were colonized with CPE. Conclusions: CTX-M ESBLPE are established in the general population in England and prevalence is particularly high in people from certain countries of birth or with recent travel. We recommend that these findings be taken into account in guidance on the empirical management of patients presenting with a likely Enterobacteriaceae infection.

Indexed as

AdolescentAdultAgedAged, 80 and overbeta-LactamasesEmigration and ImmigrationEnglandEnterobacteriaceaeEnterobacteriaceae InfectionsFecesFemaleHumansMaleMiddle AgedPrevalenceRisk Factorsbeta-Lactamases

Identifiers

PMID29514211
PMCPMC5909627
OpenAlexW2789573105

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.